CIAC001 

CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC₅₀=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction^[1].

PKM2^[1]

CIAC001 (10 μM; 6 h) inhibits LPS (200 ng/mL)-induced microglia morphology change in BV-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CIAC001 (20 μg/kg, and 0.2 mg/kg, i.p, once daily for 7 days) dose-dependently attenuates Naloxone (HY-137279, opioid receptor antagonist) precipitated withdrawal jumps and significantly inhibits the development of morphine-induced behavioral sensitization during the induction period, in morphine-dependent mice^[1].
CIAC001 (20 mg/kg, i.p, once daily for 7 days)has no apparent potential for memory decline or cognitive impairment in mice Y maze test^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

339.43

C₂₀H₂₅N₃O₂

2649154-82-3

CC(N1N=CC=N1)C2=CC(O)=C(C(O)=C2)[C@@H]3C=C(CC[C@H]3C(C)=C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jin S, et al. Cannabidiol Analogue CIAC001 for the Treatment of Morphine-Induced Addiction by Targeting PKM2. J Med Chem. 2023 Aug 24;66(16):11498-11516.  [Content Brief]